GB202209622D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB202209622D0
GB202209622D0 GBGB2209622.6A GB202209622A GB202209622D0 GB 202209622 D0 GB202209622 D0 GB 202209622D0 GB 202209622 A GB202209622 A GB 202209622A GB 202209622 D0 GB202209622 D0 GB 202209622D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2209622.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Priority to GBGB2209622.6A priority Critical patent/GB202209622D0/en
Publication of GB202209622D0 publication Critical patent/GB202209622D0/en
Priority to PCT/GB2023/051701 priority patent/WO2024003557A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2209622.6A 2022-06-30 2022-06-30 Compounds Ceased GB202209622D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2209622.6A GB202209622D0 (en) 2022-06-30 2022-06-30 Compounds
PCT/GB2023/051701 WO2024003557A1 (en) 2022-06-30 2023-06-29 Sulfoximines as inhibitors of lysyl oxidase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2209622.6A GB202209622D0 (en) 2022-06-30 2022-06-30 Compounds

Publications (1)

Publication Number Publication Date
GB202209622D0 true GB202209622D0 (en) 2022-08-17

Family

ID=82802660

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2209622.6A Ceased GB202209622D0 (en) 2022-06-30 2022-06-30 Compounds

Country Status (2)

Country Link
GB (1) GB202209622D0 (en)
WO (1) WO2024003557A1 (en)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10216144A1 (en) 2002-04-12 2003-11-06 Bayer Ag New 2-phenyl-4-phenoxy-3(2H)-pyridazinone derivatives useful as lysyl oxidase inhibitors for preventing or treating fibrotic diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US9161922B2 (en) 2005-07-01 2015-10-20 Case Western Reserve University Amine oxidase inhibitors
AU2008337286B2 (en) 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
US20100203062A1 (en) 2009-02-06 2010-08-12 Ingeborg Stalmans Methods and Compositions for Treatment of Neovascularization
CN102711821A (en) 2009-08-21 2012-10-03 吉联亚生物科技有限公司 Therapeutic methods and compositions
WO2011022670A1 (en) 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
JP2013506005A (en) 2009-09-29 2013-02-21 ギリアド バイオロジクス，インク． Methods and compositions for the treatment of ocular fibrosis
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2012139045A1 (en) 2011-04-08 2012-10-11 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
WO2014152122A2 (en) 2013-03-15 2014-09-25 Children's Medical Center Corporation Methods of altering vascular permeability and uses thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP6697809B2 (en) 2015-03-06 2020-05-27 ファーマケア，インク． Fluorinated lysyl oxidase-like 2 inhibitors and their use
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
EP3317258A4 (en) 2015-07-01 2019-06-26 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
US20180215727A1 (en) 2015-07-23 2018-08-02 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
AU2020317374A1 (en) 2019-07-25 2022-02-03 Pharmaxis Ltd. Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof

Also Published As

Publication number Publication date
WO2024003557A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
GB202200735D0 (en) Compounds
GB202303419D0 (en) Compounds
GB202208643D0 (en) Compounds
GB202300021D0 (en) Compounds
GB202214796D0 (en) Compounds
GB202208151D0 (en) Compounds
GB202208160D0 (en) Compounds
GB202201996D0 (en) Compounds
GB202305212D0 (en) Compounds
GB202303387D0 (en) Compounds
GB202303230D0 (en) Compounds
GB202302871D0 (en) Compounds
GB202302237D0 (en) Tryptophan-based compounds
GB202302032D0 (en) Compounds
GB202300995D0 (en) Compounds
GB202301000D0 (en) Compounds
GB202301008D0 (en) Compounds
GB202301012D0 (en) Compounds
GB202301024D0 (en) Compounds
GB202300922D0 (en) Compounds
GB202219706D0 (en) Compounds
GB202219534D0 (en) Compounds
GB202217844D0 (en) Compounds
GB202217330D0 (en) Compounds
GB202216695D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)